CO5640135A2 - Derivados de 4-(4-(heterociclilalcoxi)-1-(heterociclil-carbonil)piperidina y compuestos relacionados como antagonistas de histamina h3 para el tratamiento de enfermedades neurologicas tales como alzheimer - Google Patents

Derivados de 4-(4-(heterociclilalcoxi)-1-(heterociclil-carbonil)piperidina y compuestos relacionados como antagonistas de histamina h3 para el tratamiento de enfermedades neurologicas tales como alzheimer

Info

Publication number
CO5640135A2
CO5640135A2 CO05101708A CO05101708A CO5640135A2 CO 5640135 A2 CO5640135 A2 CO 5640135A2 CO 05101708 A CO05101708 A CO 05101708A CO 05101708 A CO05101708 A CO 05101708A CO 5640135 A2 CO5640135 A2 CO 5640135A2
Authority
CO
Colombia
Prior art keywords
alkyl
heterocyclyl
heteroaryl
aryl
alkoxy
Prior art date
Application number
CO05101708A
Other languages
English (en)
Spanish (es)
Inventor
Mark James Bamford
David Kenneth Dean
David M Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5640135A2 publication Critical patent/CO5640135A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO05101708A 2003-04-10 2005-10-06 Derivados de 4-(4-(heterociclilalcoxi)-1-(heterociclil-carbonil)piperidina y compuestos relacionados como antagonistas de histamina h3 para el tratamiento de enfermedades neurologicas tales como alzheimer CO5640135A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0308333.4A GB0308333D0 (en) 2003-04-10 2003-04-10 Novel compounds

Publications (1)

Publication Number Publication Date
CO5640135A2 true CO5640135A2 (es) 2006-05-31

Family

ID=9956580

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05101708A CO5640135A2 (es) 2003-04-10 2005-10-06 Derivados de 4-(4-(heterociclilalcoxi)-1-(heterociclil-carbonil)piperidina y compuestos relacionados como antagonistas de histamina h3 para el tratamiento de enfermedades neurologicas tales como alzheimer

Country Status (22)

Country Link
US (1) US20060205774A1 (enExample)
EP (1) EP1610786B9 (enExample)
JP (1) JP2006522771A (enExample)
KR (1) KR20050111638A (enExample)
CN (1) CN1805747A (enExample)
AR (1) AR044006A1 (enExample)
AT (1) ATE365039T1 (enExample)
AU (1) AU2004228949B2 (enExample)
BR (1) BRPI0409110A (enExample)
CA (1) CA2521899A1 (enExample)
CO (1) CO5640135A2 (enExample)
DE (1) DE602004007119T2 (enExample)
ES (1) ES2288681T3 (enExample)
GB (1) GB0308333D0 (enExample)
IS (1) IS8118A (enExample)
MA (1) MA27726A1 (enExample)
MX (1) MXPA05010816A (enExample)
NO (1) NO20055256L (enExample)
RU (1) RU2005134006A (enExample)
TW (1) TW200503710A (enExample)
WO (1) WO2004089373A1 (enExample)
ZA (1) ZA200507795B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
US7553964B2 (en) * 2005-06-03 2009-06-30 Abbott Laboratories Cyclobutyl amine derivatives
US7408066B2 (en) 2005-06-20 2008-08-05 Schering Corproation Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
ATE450526T1 (de) 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007035703A1 (en) 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
TW200804274A (en) 2005-10-27 2008-01-16 Ucb Sa Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
TW200730498A (en) * 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
AU2006331882A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
KR20080080201A (ko) 2005-12-21 2008-09-02 쉐링 코포레이션 히스타민 h3 길항제로서 유용한 치환된 아닐린 유도체
JP5335675B2 (ja) 2006-07-25 2013-11-06 セファロン、インク. ピリジジノン誘導体
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2124933B1 (en) * 2007-01-22 2012-10-17 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
EP2185544B1 (en) 2007-07-19 2014-11-26 Cymabay Therapeutics, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders
AU2009271414A1 (en) * 2008-06-20 2010-01-21 Metabolex, Inc. Aryl GPR119 agonists and uses thereof
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
US9284324B2 (en) 2011-12-08 2016-03-15 Taisho Pharmaceutical Co., Ltd Phenylpyrrole derivative
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
RU2717577C2 (ru) 2015-04-21 2020-03-24 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное имидазоизоиндола, способ его получения и медицинское применение
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
CN113453762B (zh) * 2019-03-05 2024-06-07 卫材R&D管理有限公司 五环杂环化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
JPH07509694A (ja) * 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体,その使用方法および遺伝子治療のための分子スイッチ
DE4407139A1 (de) * 1994-03-04 1995-09-07 Thomae Gmbh Dr K Aryl-1-azacycloalkane und deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
CA2214288C (en) * 1996-09-18 2006-07-18 Lonza Ag Process for the preparation of 1-acyl-4-arylpiperidines
EP0837065A1 (de) * 1996-10-16 1998-04-22 Ciba SC Holding AG Phenylglycidylether-HALS
US6515013B2 (en) * 2000-07-13 2003-02-04 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
WO2002006223A1 (en) * 2000-07-13 2002-01-24 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
WO2002012214A2 (en) * 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical Inc. Non-imidazole aryloxyalkylamines as h3 receptor ligands
CA2439152C (en) * 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
US20060079533A1 (en) * 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
US7459461B2 (en) * 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases

Also Published As

Publication number Publication date
KR20050111638A (ko) 2005-11-25
AR044006A1 (es) 2005-08-24
NO20055256L (no) 2006-01-10
DE602004007119T2 (de) 2008-02-21
ATE365039T1 (de) 2007-07-15
AU2004228949A1 (en) 2004-10-21
TW200503710A (en) 2005-02-01
NO20055256D0 (no) 2005-11-09
GB0308333D0 (en) 2003-05-14
BRPI0409110A (pt) 2006-03-28
CN1805747A (zh) 2006-07-19
ES2288681T3 (es) 2008-01-16
MXPA05010816A (es) 2005-12-05
MA27726A1 (fr) 2006-01-02
CA2521899A1 (en) 2004-10-21
WO2004089373A1 (en) 2004-10-21
JP2006522771A (ja) 2006-10-05
EP1610786B9 (en) 2008-02-27
US20060205774A1 (en) 2006-09-14
AU2004228949B2 (en) 2006-11-02
RU2005134006A (ru) 2006-04-10
IS8118A (is) 2005-11-08
EP1610786A1 (en) 2006-01-04
ZA200507795B (en) 2006-07-26
EP1610786B1 (en) 2007-06-20
DE602004007119D1 (de) 2007-08-02

Similar Documents

Publication Publication Date Title
CO5640135A2 (es) Derivados de 4-(4-(heterociclilalcoxi)-1-(heterociclil-carbonil)piperidina y compuestos relacionados como antagonistas de histamina h3 para el tratamiento de enfermedades neurologicas tales como alzheimer
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
HRP20080227T3 (hr) Pirolidinski derivati kao ligandi histaminskih receptora
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR048974A1 (es) Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas.
AR049739A1 (es) Derivados de aril-piridina
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
AR045602A1 (es) Derivados de benzoilpiperazinas, procesos de obtencion y composiciones farmaceuticas.
AR060658A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
AR059040A1 (es) Cis-4, 5- biaril-2- heterociclico imidazolinas como inhibidores de la mdm 2
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
AR054365A1 (es) Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
AR037418A1 (es) Derivados de benzotiazol
AR050364A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica
AR049696A1 (es) Derivados de indol
AR050281A1 (es) Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
AR059094A1 (es) Derivados de ciclohexil - sulfonamida
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.

Legal Events

Date Code Title Description
FC Application refused